Abstract
The anticonvulsant and neuroprotective properties of agonist and antagonist of metabotropic glutamate receptors (mGluRs ) have been known for 15 years or so. However, it is not yet clear whether these agents, and allied compounds, can be considered as candidate drugs for eventual use in the clinic to control the development of epilepsy, (i.e. as anti- epileptogenics), or for the control of seizures themselves (i.e. as anticonvulsants). In fact, few studies have been designed to test for these properties by, for instance, administering these agents during the chronic stages of experimental epilepsy to determine whether a tendency to generate spontaneously recurrent seizures, which often appear by epileptogenesis, could be prevented or stopped. Even in the acute stages, there are substantial differences in experimental design between the published studies. Thus, there are large variations in such factors as timing, and the route of administration of candidate drugs, the age, or species and strain of experimental animal used, and the experimental epilepsy model employed. Such variations often make it difficult to accurately assess the anticonvulsant, neuroprotective and antiepileptogenic properties of each candidate drug across a wide range of studies. This paper, will review neuroanatomical, neurochemical, neuropharmacological studies of mGluRs in animal models and in patients with temporal lobe epilepsy, and summarize anticonvulsive and neuroprotective effects of their agonists and antagonists in different seizure and epilepsy models in order to give direction for the development of new generation antiepileptogenic and anticonvulsive drugs.
Keywords: Metabotropic glutamate receptors (mGluRs), agonists and antagonists, anticonvulsive, anti-epileptogenic, glutamate- induced epileptic discharges
Current Medicinal Chemistry
Title: Metabotropic Glutamate Receptors in the Control of Neuronal Activity and as Targets for Development of Anti-Epileptogenic Drugs
Volume: 16 Issue: 17
Author(s): Feng Ru Tang, Henry F. Bradford and Eng-Ang Ling
Affiliation:
Keywords: Metabotropic glutamate receptors (mGluRs), agonists and antagonists, anticonvulsive, anti-epileptogenic, glutamate- induced epileptic discharges
Abstract: The anticonvulsant and neuroprotective properties of agonist and antagonist of metabotropic glutamate receptors (mGluRs ) have been known for 15 years or so. However, it is not yet clear whether these agents, and allied compounds, can be considered as candidate drugs for eventual use in the clinic to control the development of epilepsy, (i.e. as anti- epileptogenics), or for the control of seizures themselves (i.e. as anticonvulsants). In fact, few studies have been designed to test for these properties by, for instance, administering these agents during the chronic stages of experimental epilepsy to determine whether a tendency to generate spontaneously recurrent seizures, which often appear by epileptogenesis, could be prevented or stopped. Even in the acute stages, there are substantial differences in experimental design between the published studies. Thus, there are large variations in such factors as timing, and the route of administration of candidate drugs, the age, or species and strain of experimental animal used, and the experimental epilepsy model employed. Such variations often make it difficult to accurately assess the anticonvulsant, neuroprotective and antiepileptogenic properties of each candidate drug across a wide range of studies. This paper, will review neuroanatomical, neurochemical, neuropharmacological studies of mGluRs in animal models and in patients with temporal lobe epilepsy, and summarize anticonvulsive and neuroprotective effects of their agonists and antagonists in different seizure and epilepsy models in order to give direction for the development of new generation antiepileptogenic and anticonvulsive drugs.
Export Options
About this article
Cite this article as:
Tang Ru Feng, Bradford F. Henry and Ling Eng-Ang, Metabotropic Glutamate Receptors in the Control of Neuronal Activity and as Targets for Development of Anti-Epileptogenic Drugs, Current Medicinal Chemistry 2009; 16 (17) . https://dx.doi.org/10.2174/092986709788612710
DOI https://dx.doi.org/10.2174/092986709788612710 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial: Advances in the Treatment of Neurodegenerative Diseases and Epilepsy
Current Pharmaceutical Design Topiramate Decelerates Bicarbonate-Driven Acid-Elimination of Human Neocortical Neurons: Strategic Significance for its Antiepileptic, Antimigraine and Neuroprotective Properties
CNS & Neurological Disorders - Drug Targets Tuberculosis Infections of the Central Nervous System
Central Nervous System Agents in Medicinal Chemistry Could Hippocampal Neurogenesis be a Future Drug Target for Treating Temporal Lobe Epilepsy?
CNS & Neurological Disorders - Drug Targets Understanding Genotypes and Phenotypes of the Mutations in Voltage- Gated Sodium Channel α Subunits in Epilepsy
CNS & Neurological Disorders - Drug Targets Recent Developments of Thalidomide Derivatives Possessing Anti-Inflammatory Activity
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Brain Aging and Disorders of the Central Nervous System: Kynurenines and Drug Metabolism
Current Drug Metabolism Recent Development in Substituted Benzothiazole as an Anticonvulsant Agent
Mini-Reviews in Medicinal Chemistry Aquaporins and Glia
Current Neuropharmacology Mitochondriotropic Cationic Vesicles A Strategy Towards Mitochondrial Gene Therapy
Current Pharmaceutical Biotechnology Augmentation of Citalopram with Aspirin for Treating Major Depressive Disorder, a Double Blind Randomized Placebo Controlled Clinical Trial
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Prophylactic Use of Antiepileptic Drugs in Patients Scheduled for Neurosurgery
Current Pharmaceutical Design Aligning Animal Models of Clinical Germinal Matrix Hemorrhage, From Basic Correlation to Therapeutic Approach
Current Drug Targets Understanding Effects of Psychological Stress on Physiology and Disease Through Human Stressome - An Integral Algorithm
Current Bioinformatics Hematologic Abnormalities in the Antiphospholipid Syndrome
Current Rheumatology Reviews In Silico Approaches Towards the Understanding of the Structure- Function Relationships in Metabotropic Glutamate Receptors (mGluRs) and other Family C GPRCs
Current Pharmaceutical Design Isoprostanes as Biomarkers and Mediators of Oxidative Injury in Infant and Adult Central Nervous System Diseases
Current Neurovascular Research Three Decades of P-gp Inhibitors: Skimming Through Several Generations and Scaffolds
Current Medicinal Chemistry Pharmacogenetics of Opioids for the Treatment of Acute Maternal Pain During Pregnancy and Lactation
Current Drug Metabolism Potential Strategies for Minimizing Mechanism-Based Inhibition of Cytochrome P450 3A4
Current Pharmaceutical Design